In melanoma cells resistant to trametinib, few damaging mutations were found including L437F and K438M substitutions in ERBB4 in 11_TRAR, G388R variant of FGFR4, and E36A variant of platelet-derived growth factor receptor alpha (PDGFRA) in 21_TRAR, and E519K alteration of RASGRP4 in 17_TRAR cells. This evidence concerns the gene RASGRP4 and melanoma.